Cancer Immunotherapy and Biomarkers

This paper identifies polyfunctional IL-21+ IFNγ+ T follicular helper cells as drivers of ICI-induced diabetes and shows JAK inhibitors can prevent this autoimmune condition.

This study maps spatial tumour-immune interactions in melanoma and identifies how their organization affects anti-PD1 therapy efficacy.

This study identifies OPG-secreting CAFs as immunosuppressive stromal cells and shows that blocking OPG promotes immune infiltration and tumor regression in mouse models.

This study identifies PTPN1 and PTPN2 as cooperative regulators of cancer immune evasion, showing their inhibition enhances immune response and synergizes with anti-PD1 therapy.

This study shows mutant p53R172H in pancreatic cancer enhances immunosuppressive chemokine Cxcl1 expression via enhancer activation, reducing immune checkpoint inhibitor efficacy.

This study identifies a new subtype of myofibroblastic cancer-associated fibroblasts expressing high B7-H3 in colorectal cancer, which is associated with poor prognosis.

This study shows that targeting CD38 improves T cell function and restores response to immunotherapy in melanoma models.

This study identifies the KEAP1-NRF2 pathway as a driver of CD8 T cell exhaustion by regulating the prostacyclin receptor PTGIR.

This paper introduces TIME_ACT, a transcriptomic signature predicting immune checkpoint blockade response across cancers, validated using histopathology and multiple cohorts.

This paper uses CRISPR to edit Rictor in myeloid cells via lipid nanoparticles, reprogramming the tumor microenvironment to enhance anti-tumor immunity in a breast cancer liver metastasis model.

This study shows that constitutive IκBζ expression in melanoma promotes tumor growth and immunotherapy resistance by suppressing cytokine production and immune cell recruitment.

This study develops the Tumor Microbiome Survival Index (TMSI) to predict cancer patient survival and drug sensitivity across multiple cancer types based on intra-tumor microbiome data.

This study identifies a secreted form of Clever-1 that suppresses T cell responses and reduces anti-PD-1 efficacy in cancer, suggesting it as a therapeutic target and biomarker.

This study identifies a p53 mutation-specific immunotherapy strategy for ovarian cancer by targeting AREG and PD-L1, showing efficacy in mouse models and patient-derived organoids.

This study investigates the effect of dietary fiber on immune checkpoint blockade efficacy in murine tumor models and finds inconsistent results across different models.

The paper identifies pathogenic PD-L1 nsSNVs that alter glycosylation and ICI binding through bioinformatics and experimental methods.

This study uses proteomics and immunohistochemistry to analyze tumor-immune dynamics in HGSOC, identifying mechanisms of immune escape across metastatic progression.

This study identifies factors regulating PD-L1 expression in Wilms tumor, showing chemotherapy, Wnt/β-catenin signaling, and mutations in CTNNB1 and DROSHA correlate with increased PD-L1 levels.

This paper develops a humanized mouse model of oral squamous cell carcinoma to study resistance to anti-PD1 immunotherapy and identifies mechanisms of resistance.

The paper develops a co-culture model of lung cancer organoids and peripheral blood mononuclear cells to study systemic anti-tumor immunity and predict immunotherapy outcomes.

This study uses spatial multi-omics and deep learning to identify immunotherapy response and resistance signatures in hepatocellular carcinoma.

This study shows that sulindac enhances anti-PD-L1 immunotherapy efficacy in TNBC by reducing exosomal PD-L1 and increasing T cell infiltration.

This paper introduces a multi-LLM framework to identify immunotherapy biomarkers from Ig-domain-containing genes using multi-omics data and structured prompts.

The paper investigates how myeloid-T cell interactions and B cell activation influence response to checkpoint inhibition in metastatic breast cancer using multi-omics and computational methods.

This study integrates immunohistochemistry and single-cell RNA sequencing data to characterize the immune landscape of pediatric brain and solid tumors, revealing distinct immune microenvironment features across tumor types.

This study identifies how intratumoral microbiota-derived S1P enhances the efficacy of Capecitabine-Nivolumab in CRC by modulating PD-L1 expression and T cell dynamics.

This study shows KDM5A enhances MHC-I antigen presentation and improves antitumor immunity in response to PD-1 checkpoint blockade in cancer patients.

This study develops a computational model of the HNSCC tumor microenvironment to identify subtype-specific resistance mechanisms and predict therapeutic targets for immunotherapy.

This paper develops an active soluble LIGHT protein that promotes immune cell infiltration and delays tumor growth in a melanoma model.